author-photo

Damian Handisides

17

Papers

89

Citations

Citation Trend

Filter By

Papers (15) Sort By

Journal Conference Others

Renin and Survival in Patients Given Angiotensin II for Catecholamine-Resistant Vasodilatory Shock.

2020 American Journal of Respiratory and Critical Care Medicine
Show All
- Source
- Cite
- Save
Citations (20)
Regional differences in the treatment of refractory vasodilatory shock using Angiotensin II in High Output Shock (ATHOS-3) data

2019 Journal of Critical Care
Show All
- Source
- Cite
- Save
Citations (4)
Phase I study of TH-302, a hypoxia-activated cytotoxic prodrug, in subjects with advanced leukemias.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (7)
Final Results of a Phase 1/2 Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of Evofosfamide, a Hypoxia-Activated Prodrug, and Dexamethasone with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma

2016 Blood
Show All
- Source
- Cite
- Save
Citations (1)
Preliminary safety and efficacy of evofosfamide (TH-302), an investigational hypoxia-activated prodrug, combined with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma (RR MM).

2015 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Preliminary safety and efficacy of TH-302, an investigational hypoxia-targeted drug, and dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RR MM).

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
A Phase 1/2 Trial of TH-302 and Dexamethasone without or with Bortezomib (TBorD) in Patients with Relapsed/Refractory Multiple Myeloma

2014 Blood
Show All
- Source
- Cite
- Save
Citations (3)
Synergistic Induction of Apoptosis in Multiple Myeloma Cells by Bortezomib and Hypoxia-Activated Prodrug TH-302, In Vivo and In Vitro

2013 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (45)
Hypoxia Activated Pro-Drug TH-302 Induces Hypoxia-Dependent Anti-leukemia Activity in vitro and in vivo

2013 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (1)
Abstract 4641: Hypoxia activated pro-drug TH-302 induces hypoxia-dependent anti-leukemia activity in vitro and in vivo

2012 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)